Investor mix
8 investors on record; lead investors include Apricot Capital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 50% |
| Bank & private debt | 1 | 13% |
| Other / undisclosed | 3 | 38% |
Developer of TCR-T immune cell therapy drugs for solid tumors
8 investors on record; lead investors include Apricot Capital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 50% |
| Bank & private debt | 1 | 13% |
| Other / undisclosed | 3 | 38% |